We've got family mealtimes covered every day until 3pm during the October half-term! When you book a table to eat with us, your Kids Eat Free.
Little ones can tuck into a Hoppy Meal, with favourites like cheeseburgers, chicken tenders, fries or salad, plus a drink - all on us.
Book Now
Just by chance this article from Just Drinks below which has BrewDog and Keurig Dr Pepper, who are both in a new airport partnership in Orlando (that can easily expand into many further airports etc).
Tilray's CEO told Just Drinks “the most important thing” was “building the strongest brand in BrewDog”
$TLRY “Irwin said BrewDog could bounce back and return to annual sales of £350m/yr, up from about £225m presently, and become profitable again with the right support. HE BELIEVES IT COULD BE WORTH AS MUCH AS £2BN IN THE FUTURE.”
That’s DIVERSITY 👊🔥
| 50% OFF AF IN BARS |
|---|
| Going alcohol free this October? We've got you covered. Join BrewDog Treats and you'll get 50% off AF beer in bar** as well as a host of other rewards on us. Go on, treat yourself. |
|---|
| 15% OFF ALCOHOL FREE |
|---|
| Life’s about balance. Sometimes you want a beer. Sometimes you want an alcohol free beer. Sometimes you might even want [dramatic gasp] something that isn’t beer. For the times you want to lay off the booze, we’ve got an epic selection of AF beers for you to try with 15% off, including our 48 mixed pack for less than £1 a can.* |
|---|
brewdog official
This is haze done properly. Say hello to Cloud Engine.
We've double dry hopped for a flavour bomb of mango, passionfruit and ripe citrus, layered with a grape and gooseberry punch.
The result? A silky-smooth mouthfeel with all the hop hit and none of the bitterness. Oh, and an pretty damn cool can design (if we do say so).
Now live at our bio link and in bars.
This short best of 3 game WildCard series, are all 3 games if necessary played in these same parks
Tilray Beers have major, multiple sales outlets in 3 of these massive Stadiums.
Rumor or Leak: I read about Tilray Brews going into more Professional Stadiums
-Tilray has a massive opportunity to penetrate stadiums in Ohio, Buffalo, and the Carolinas.
THE NEXT BIG WAVE: REGIONAL EXPANSION CATALYSTS
With these packed USA stadiums bringing in $40,000 to $100,000 for these 4 hour games or concerts its a great upgrade for Tilray Beers.
Another great piece of Infused News -
- Austin City Limit concerts just announced they are now allowing THC Infused Beverages
September 30, 2026 Anthony Varrell, TDR newsletter
Cannabis markets spent late summer treating the DEA rescheduling hearing as finished business — testimony done, briefs filed, only the ALJ’s recommendation left to drop. Instead of that recommendation, Judge Derek Julius issued a stay. Three hearing opponents want a late-September GAO report on scheduling procedures added to the record, and Julius paused the case until after 10/13 when he decides whether it comes in. The substance of the marijuana rule hasn’t changed. The calendar just did.
For six weeks the only thing left in the DEA's marijuana rescheduling hearing was the recommendation itself. Testimony wrapped in July, final briefs landed in August, and every trader in the sector has been refreshing the docket waiting for Chief Administrative Law Judge Derek Julius to send his findings to Administrator Terry Cole. On Tuesday he sent something else: a stay.
The trigger was a motion from the National Drug and Alcohol Screening Association, DUID Victim Voices and Dr. Kenneth Finn — three of the hearing's designated opponents — asking to reopen the record to include a Government Accountability Office report published September 23. Julius wrote that he "finds merit in this argument that, if the record were to be extended to also include the GAO Report, a stay would be warranted to await briefing on it," and paused the proceeding while he decides whether to let it in. DEA has until October 13 to file a response of up to 20 pages on whether the record should be reopened. Other parties may respond on the same terms but aren't required to.
What the GAO is
The Government Accountability Office is Congress's auditor. Founded in 1921 as the General Accounting Office and renamed in 2004, it's an independent, nonpartisan agency in the legislative branch, run by a Comptroller General who serves a single 15-year term specifically so no president can lean on him. Its roughly 3,000 staff investigate how federal agencies spend money and follow their own rules, and they do it on request from members of Congress. GAO findings carry weight because they're methodical and rarely wrong on facts, but its recommendations are advisory. Agencies "concur" or "non-concur," and GAO tracks whether they follow through — sometimes for years.
GAO has been circling cannabis policy all year. Its August banking report, requested by Senators Warren, Warnock, Smith and Fetterman, found that about 1,000 banks and credit unions serve cannabis businesses under a 2014 FinCEN guidance built on a Justice Department memo that was rescinded in 2018, and that no institution has ever been penalized solely for serving a state-licensed operator. It's the same posture GAO takes in every drug-policy review: document the gap between what agencies do and what they've written down, then tell them to write it down.
What the scheduling report says
The September report — GAO-26-108623 — is 31 pages on how DEA and FDA make scheduling decisions. Its headline finding is that DEA has followed HHS on every single substance where a recommendation was required: 95 of 95 from 2020 through 2025, with 84 finalized in alignment and the remaining 11 later placed in Schedule I, also as HHS recommended. Disagreements between the agencies "are rare," officials told GAO, and get resolved privately before public comment.
The "gaps" are procedural. DEA "does not have any policies or procedures regarding how its staff are to conduct evaluations or schedule substances" — no written playbook for collecting data, running eight-factor analyses or weighing HHS input. FDA lacks written criteria for assessing a drug's "potential for abuse" relative to other substances. The FDA-NIDA coordination MOU is more than 40 years old. GAO made three recommendations, all of which the agencies accepted. It did not review the marijuana rulemaking and reached no conclusion about whether it was handled properly.
Why opponents want it in the record
NDASA and its co-movants are making a straightforward play: if the agency that's about to reschedule marijuana has no written procedure for doing so, the outcome is arbitrary and the ALJ should say so. It's the same argument SAM is running in the D.C. Circuit against the April medical-only rule, and the GAO report gives it a citation.
The problem is that the report cuts the other way at least as hard. The eight-factor analysis for marijuana was done by HHS, whose 2023 recommendation ran to hundreds of pages and was reviewed by the Office of Legal Counsel, which concluded it was legally sufficient and that DEA must give it significant deference. A GAO finding that DEA has followed HHS 95 times out of 95 is not evidence that DEA should break the streak on the 96th. If anything, it tells the ALJ that departing from HHS now would be the anomaly requiring explanation. DEA's own final brief already leaned on this: the agency said it must give "significant deference" to HHS's "extensive ten-month study" and asked Julius to "expeditiously recommend" Schedule III.
Is this Julius being careful, or Julius being slow?
Careful. An administrative law judge's job is to build a record that survives review, and the fastest way to lose one on appeal is to ignore a motion to admit relevant new evidence from a party with standing. Julius hasn't reopened the record. He's paused, asked DEA whether it objects, and given the other participants a chance to weigh in. That's the minimum process due on a motion like this, and it inoculates his eventual recommendation against the argument that he refused to consider a federal watchdog's findings. The judge who ran the Biden-era hearing into the ground did so partly by getting procedure wrong; Julius appears determined not to repeat it.
It also gives DEA an opening. The agency's 20-page response is a chance to argue that the GAO report is irrelevant to the merits — it reviewed procedures, not this rulemaking — or, more cleverly, that it confirms the agency's consistent deference to HHS. Either way DEA gets to frame the report before the opponents do.
What it does to the timeline
Two paths. If Julius denies the motion after October 13, the record stays closed and his recommendation could still land in late October. If he grants it, expect a supplemental briefing schedule of a few weeks, which pushes the recommendation into November or December — after the midterms, and squarely into the same window as the hemp deadline. Markets that had priced a recommendation "any day now" are going to have to re-price patience.
The substance hasn't changed. HHS recommended Schedule III, OLC said defer, DEA's own lawyers argued for it in the hearing, and the GAO just documented that DEA has never once done otherwise. The stay is a procedural pause, not a signal. The opponents got two extra weeks and a footnote. What they didn't get is a new argument.
From the Pacific Northwest’s ultimate beer innovators: a masterclass in craft R&D, now mixing real spirits
BEND, Ore., Sept. 30, 2026 (GLOBE NEWSWIRE) -- 10 Barrel Brewing, the Bend-born craft beer brand known for bold beers, big personality, and bringing people together for a good time, by Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is excited to announce the launch of Salty Sips Blackberry Refresher, the latest addition to its growing portfolio of the Salty Sips ready-to-drink cocktails line.
Built for those looking for refreshing flavor without the heavy sweetness, Salty Sips Blackberry Refresher blends vodka, real fruit juice, a hint of mint and a pinch of sea salt into an easy-drinking, low sugar cocktail that's crisp, balanced, and straight-up crushable. Crafted at 5.0% ABV, the new flavor delivers refreshing blackberry character and bright fruit notes, making it the perfect companion for warm afternoons, backyard hangs, river floats, and wherever the day takes you.
Inspired by the simple pleasure of fresh fruit and the refreshing kick of a lightly salted snack on a summer day, Blackberry Refresher continues the Salty Sips philosophy of delivering bold flavor with less sugar and an approachable ABV. Made with real fruit juice and a pinch of sea salt, the cocktail offers a clean, refreshing finish that keeps you coming back for another sip.
"The launch of Salty Sips Watermelon Refresher in the spring was such a hit with our fans that we were pumped to extend the product line with Blackberry Refresher, a product that feels both refreshing and flavorful without weighing you down," said Moo Eakin, Senior Brand Manager at 10 Barrel Brewing Co. "The combination of real blackberry juice, vodka, and a pinch of sea salt creates a low-sugar, balanced cocktail that's easy to enjoy whether you're on the mountain, at the lake, or hanging with friends."
The second member to the Salty Sips lineup follows the successful launch of Watermelon Refresher and builds the foundations of a portfolio of innovative cocktails designed for consumers seeking flavor-forward, easy-drinking options that fit today's evolving lifestyles. With just 5.0% ABV and low sugar, Salty Sips Blackberry Refresher delivers a modern take on refreshment without sacrificing taste.
Salty Sips Blackberry Refresher is now available in convenient 4-packs in select markets across the Pacific Northwest, with expanded distribution planned in additional western U.S. markets.
For more information, visit 10 Barrel Brewing.
About 10 Barrel Brewing Co.
10 Barrel Brewing Company is a craft brewery based in Bend, Oregon, featuring innovative beers brewed locally at each of its four brewpub locations in Bend, Portland, and Boise. 10 Barrel has one simple mindset: Brew beer, drink beer, and have fun doing it. For more information, visit 10 Barrel Brewing and follow @10barrelbrewing on social.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages.
Big cheers to @breckdistillery! Recognized by Forbes for their latest product, Breck Vodka Seltzer.
Congratulations to the Breckenridge team, your relentless passion and dedication have not only achieved this remarkable milestone but have also transformed the way consumers enjoy their beverages.
Read the article: https://forbes.com/sites/bradjaphe/2026/09/06/the-worlds-highest-bourbon-distillery-enters-the-vodka-seltzer-space/
#BreckenridgeDistillery $TLRY
ELLON, Scotland and LONDON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- BrewDog, a leader in U.K. craft beer and one of the world’s most recognised beer brands, owned by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), today announced a series of senior leadership appointments designed to strengthen execution, sharpen brand and commercial focus, and support BrewDog’s next phase of growth across the United Kingdom and international markets.
The appointments reflect BrewDog’s continued investment in the people, capabilities, and leadership needed to unlock the full potential of its iconic global brand and build on the momentum of its next chapter as part of the Tilray Brands family.
The senior leadership appointments include:
Rajnish Ohri, President, International at Tilray Brands, said, “We are entering an exciting new chapter for BrewDog — one defined by renewed ambition, stronger execution and a clear vision for the future. BrewDog is an iconic global brand with an incredible community, talented people, great beer and enormous potential. As part of the Tilray Brands family, we are investing in the leadership, capabilities and focus needed to build on everything that has made BrewDog special while bringing even greater ambition to where we go next.”
Mr. Ohri continued, “These appointments reflect our commitment to building a stronger BrewDog for the future, with the right people empowered to lead and the focus, energy and leadership needed to execute effectively. Our ambition is clear: to make BrewDog stronger, continue to innovate and lead, and build one of the world’s most exciting and influential craft beer brands for the long term. BrewDog’s next chapter is underway, and we believe its best years are ahead.”
Together, the strengthened leadership bench brings additional focus across brand building, consumer engagement, hospitality, category strategy and international commercial growth, supporting BrewDog’s strategy to strengthen the core brand, accelerate innovation and unlock opportunities across retail, hospitality and global markets.
With an expanded leadership team, the strength and scale of Tilray Brands behind it, and a clear focus on long-term growth, BrewDog is building for the future with renewed momentum, stronger execution and confidence in what its teams can accomplish together.
About BrewDog
BrewDog has always had one mission: to make people as passionate about great beer as we are. From iconic classics like Punk IPA, to crowd-pleasers like Lost Lager and Wingman, to boundary-pushing innovations like NanoDog, BrewDog has been brewing bold, distinctive beers since 2007. Born in Scotland and built by a passionate community of beer lovers, BrewDog has grown into one of the world’s most recognisable craft beer brands, with a global presence spanning breweries, bars and distribution across multiple international markets. BrewDog’s future continues to be shaped by the three things that matter most: People, Planet and Beer.
For more information, visit www.brewdog.com or follow u/BrewDog on social media.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow u/Tilray on all social platforms.
NEW OWNERS. THEIR ROUND.
We’re starting this new chapter the right way - with a BrewDog Headliner on us.**
Log in or sign up to BrewDog Treats to claim your beer.
Under Tilray ownership, BrewDog is back on the front foot — with fresh investment, renewed energy and award-winning beers driving the next chapter for one of the UK and Europe’s biggest craft beer brands.
ELLON, Scotland and LONDON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- BrewDog, by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), is launching a major multi-platform marketing campaign to make one message unmistakable: BrewDog is entering a new era under Tilray ownership, with fresh investment, renewed energy and strong backing behind its beers, bars, people and next chapter of growth.
Irwin D. Simon, Chairman and Chief Executive Officer, Tilray Brands, comments: “This is BrewDog’s first major campaign in a long time, and it is only the beginning. Since acquiring BrewDog, Tilray has moved quickly to put real capital, focus and operating discipline behind the business, including nearly £50 million of investment across operations, working capital, people and the platform needed to support growth. BrewDog is one of the biggest and most recognised beer brands in the UK and across Europe, and we see tremendous opportunity to re-energise it, strengthen its connection with consumers, and build it into an even bigger global business. We are proud to keep brewing BrewDog beer in Ellon, proud to honour its Scottish brewing heritage and fully committed to backing the people, beers, bars, and brewing excellence that make BrewDog such a great beer brand. This campaign is a clear signal of our commitment to the brand, and it is one of many investments we intend to make as we drive BrewDog’s next chapter of growth.”
The campaign will bring that message to market through major out-of-home and above-the-line activity across high-impact consumer, customer, and trade touchpoints. Launching on 21 September, it includes large-format outdoor advertising, digital screens in high-traffic areas and a letter from Tilray, BrewDog’s new owner, in 70,000 print copies of City AM. The City AM letter outlines Tilray’s commitment to BrewDog’s future, including renewed investment in the brand, its people, bars, and brewing heritage.
The creative carries the stand-out lines BrewDog fans and customers expect from the brand, including ‘No More Cunning Stunts. Just Great Beer’ alongside Punk IPA, ‘We’ve Flipped the Bird’ alongside Wingman and ‘A Little Less Allegation’ alongside Elvis Juice. Together, the work draws a confident line under the past while keeping BrewDog’s bold, irreverent personality front and centre.
Stuart Harrison, Chief Growth Officer, BrewDog, comments: “For our customers and trade partners, this campaign is just the beginning — and a clear way to show that BrewDog is entering a new era. Under Tilray ownership, we are investing behind the brand, backing our retail, wholesale and on-trade partners, and giving them the tools, offers and visibility to drive footfall, rate of sale and profitable growth. At the centre of that growth is great beer quality — the beers consumers love and the consistency, credibility, and performance our partners expect from BrewDog. We have the scale, recognition, and portfolio to win with consumers and deliver for customers, and we could not be more excited to work with our partners to capture the opportunity ahead.”
John Beasley, Chief Marketing Officer, BrewDog, comments: “BrewDog has always been at its best when it brings energy, attitude, and ambition to the beer category. Under New Ownership is more than a campaign; it is a statement that BrewDog is back with focus, investment, and the creative firepower to reignite momentum. We are here to support our partners, excite customers and remind the market why BrewDog remains one of the UK and Europe’s greatest beer brands.”
The campaign follows strong momentum across BrewDog’s beer portfolio, drinks platform and innovation pipeline. BrewDog recently swept up at the 2026 World Beer Awards, with Hazy Jane, Wingman and Mackie’s Two Scoops earning Gold and Scotland Country Winner awards, while Punk IPA, Lost Lager, Black Heart, and Mello were recognised among the World’s Best Beers.
To support the campaign, BrewDog will offer high-impact promotions and activations across supermarkets, on-trade, convenience, BrewDog bars and online. In grocery, BrewDog will offer £3 four-packs of Punk IPA direct to consumers, backed by high-impact in-store media, digital screens, social activity, and fixture messaging designed to drive visibility, footfall, and rate of sale. The discounted packs will also be available on BrewDog.com for a limited time.
To help pubs and bars bring that momentum to customers, BrewDog is giving new and existing on-trade customers the chance to win one of up to 1,000 free kegs of Wingman, session IPA. Promoted through trade press, route-to-market customers and the field sales team, operators simply register their interest before 12th October for the chance to win. Full terms and conditions apply.
In October, convenience retailers will be able to buy cases of Punk IPA and Hazy Jane at strong promotional pricing in participating wholesalers, giving them a timely reason to stock BrewDog’s leading beers and pass the saving on to shoppers. High-impact depot and in-store visibility will aim to drive distribution and rate of sale.
Across BrewDog’s UK and Ireland bars, the campaign will bring the ‘Under New Ownership’ message to life through high-impact customer touchpoints from the moment guests walk through the door. Customers will also be invited to raise a glass to BrewDog’s next chapter with a ‘Pint on the New Owner’ available through BrewDog Treats, giving fans and supporters a reason to come in, celebrate the brand’s future and be part of what comes next.
Since acquiring BrewDog, Tilray has invested £50 million to stabilise business operations and has reopened 16 BrewDog bars, including an industry-first community bar in Inverurie, Scotland. BrewDog has also strengthened its growth platform through new partnerships and high-profile brand moments, including a partnership with Underbelly, a five-year official beer partnership with Leicester Tigers, the £1 million World Cup bar tab and Park IPA, a summer out-of-home campaign with Deliveroo that put 20,000 cold cans of Punk IPA into consumers’ hands. Tilray has also expanded BrewDog’s platform beyond its core portfolio. Earlier this year, Tilray, the fourth largest craft brewer in the U.S., introduced 24 Tilray-owned American craft beers into BrewDog bars, including SweetWater, Montauk, 10 Barrel, Shock Top, Alpine, Green Flash and Blue Point, expanding choice for UK consumers and showcasing BrewDog’s bar platform. That platform is also supporting new formats and occasions, including the UK launch of HiBall Energy Drink and BrewDog’s Liquid Visions, a premium craft beer series featuring new hop varieties, fresh beer styles, and creative collaborations. HiBall is also now the official energy drink partner of Wolverhampton Wanders Football Club.
Across supermarkets, pubs, bars and BrewDog’s UK and Ireland venues, the ‘Under New Ownership’ campaign gives consumers, customers and trade partners a clear reason to get behind BrewDog’s next chapter — with great beer, strong promotions and the energy of a brand moving forward with renewed focus, confidence and momentum.
About BrewDog BrewDog has always had one mission: to make people as passionate about great beer as we are.
From iconic classics like Punk IPA, to crowd-pleasers like Lost Lager and Wingman, to boundary-pushing innovations like NanoDog, BrewDog has been brewing bold, distinctive beers since 2007.
Born in Scotland and built by a passionate community of beer lovers, BrewDog has grown into one of the world’s most recognisable craft beer brands, with a global presence spanning breweries, bars, and distribution across multiple international markets. BrewDog’s future continues to be shaped by the three things that matter most: People, Planet and Beer.
For more information, visit www.brewdog.com or follow @BrewDog on social media.
About Tilray Brands Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
There is a ton of focus on the sub right now about hemp drinks and the September 30th DEA deadline. But if you want to know what actually breaks the U.S. market wide open for Tilray, stop looking at state lines and start looking at the federal government.
The absolute biggest piece of alpha for this company is the Veterans Affairs (VA) Import Thesis.
🛡️ The MSO Nightmare: Federal vs. State
Every major U.S. Multi-State Operator (MSO) is playing a localized game. They exist on state-licensed islands. Even if Schedule III drops tomorrow, MSOs cannot legally transport a single gram of cannabis across state lines because they lack federal cGMP (Current Good Manufacturing Practice) certification. They are locked out of federal integration.
The Tilray Moat: Bypassing State Lines via the DEA
Tilray is built entirely differently. We own world-class, federal-grade, EU-GMP-certified facilities. More importantly, Tilray is the only major player with a proven track record of obtaining DEA approval to import medical cannabis directly into the United States for clinical trials.
When Schedule III officially takes hold and the U.S. government standardizes medical cannabis, federal institutions like the Department of Veterans Affairs will require a federally compliant supply chain. Because MSOs cannot ship across state lines, the DEA and FDA will rely on approved imports to feed federal agencies.
Tilray already has the infrastructure, the international licenses, and the historical DEA relationship to step up as the primary federal supplier.
🗓️ The Perfect Convergence Next Week
This is why the next few days are so massive.
The Bottom Line: While others are waiting for dispensaries to open up state-by-state, Tilray is positioned to capture the ultimate institutional prize: the U.S. Federal Government itself. The VA import play isn't just a side hustle—it is the ultimate Trojan Horse that allows an international powerhouse to capture America from the top down.
Stay strong, look at the structural moats, and ignore the daily noise. 💎🙌
September 18, 2026
PGP Farmer, the French biotech building the country’s first EU-GMP medical cannabis production site, has narrowed a 30-variety Dutch phenotyping trial to five elite cultivars, laying the agronomic groundwork for its 9-hectare Dordogne facility as France closes on the reforms needed for full medical cannabis rollout.
The selection, announced on September 16, 2026, comes as Paris nears publication of the decrees that will trigger the opening of the Agence nationale de sécurité du médicament (ANSM) dossier window and the resumption of the Haute Autorité de Santé (HAS) reimbursement evaluation, marking the last regulatory steps before commercial supply can begin.
The proof-of-concept, conducted in the Netherlands with applied research platform Innexo B.V., took 2,400 seeds and 1,440 transplanted plants through several months of progressive screening on vigour, yield and pharmaceutical-grade quality indicators. Five cultivars, drawn from a starting library of 30 genotypes, will advance to Phase 2, which will define the standard operating procedures for the Dordogne site.
“Selecting five elite varieties from the 30 subjected to this POC required absolute rigour, based on criteria of excellence,” said Dr Frédéric Lota, Chief Scientific Officer at PGP Farmer, who is leading the trial in partnership with Innexo B.V.
“We now have the highest-performing varieties to enter phase 2 and refine the design of the future pharmaceutical site in the Dordogne, to guarantee patients irreproachable quality in strict compliance with EU-GMP standards.”
Backed by a €3m round closed in February, PGP Farmer positions itself as the only French operator producing raw pharmaceutical materials (MPUP) for medical cannabis. The Dordogne site is designed to reach 30 tonnes of annual capacity when fully utilised, a scale intended to loosen France’s, and Europe’s, dependence on non-EU imports.
Around 75% of medical cannabis flower supplied inside the bloc still originates outside it, with Germany alone importing close to 200 tonnes in 2025.
The trial results land as France finalises the regulatory architecture for commercial rollout. On June 30, the government confirmed to the Senate that the decree covering reimbursement of cannabis-based medicines had been sent to the Conseil d’État; its examination began after the summer recess.
Publication of that decree, alongside the general authorisation decree and the ministerial orders setting cultivation conditions and product specifications, is expected in the coming weeks. PGP Farmer has contributed to the joint HAS dossier coordinated by industry body UIVEC, signed by around a dozen French and international operators.
“The generalisation of medical cannabis is finally arriving in France, after several years of waiting and delays,” said Brahim Sebart, Co-founder and Chief Executive Officer of PGP Farmer.
“What is still needed is for French companies to be able to produce on our territory. Our mission is to guarantee France a 100% French pharmaceutical raw material, at the service of patients.”
Mon, September 21, 2026
Craft beer giant BrewDog has distanced itself from its previous ownership as part of its first major marketing campaign since being taken over in a rescue deal.
The Scottish firm, which is now owned by Tilray Brands, has said there will be "a little less allegation" and "no more cunning stunts" in a series of ads.
Tilray snapped up BrewDog, which produces medicinal cannabis as well as craft beer in the US, in a £33 million deal in March after the company fell into administration.
The new owners saved a raft of venues and its franchise bars continued to operate, but 38 bars shut their doors after the insolvency, with the loss of 484 jobs.
BrewDog was co-founded by James Watt and Martin Dickie in Fraserburgh, Scotland, in 2007 and rapidly expanded on the back of booming demand for craft beer and support from crowdfund investors.
The company faced allegations from staff in 2021 about the culture of the business, with a "significant number" of former staff saying they "suffered mental illness as a result of working at BrewDog" in a letter.
Mr Watt apologised for "mistakes" and launched an independent review.
On Monday, BrewDog launched the campaign with adverts highlighting the brand was "under new ownership".
It also included a letter to customers saying it would "take good care" of the business.
"Our promise isn't to tame BrewDog, it's to let it be BrewDog again – brewed by happy people, run properly, and still fighting the good fight for better beer," it said.
It said the business would be run with "sensible work practices, community initiatives and a people-first approach".
Tilray said it has invested £50 million to stabilise BrewDog operations, relaunched 16 bars and launched new beers since taking over.
Irwin D Simon, chairman and chief executive of Tilray Brands said: "BrewDog is one of the biggest and most recognised beer brands in the UK and across Europe, and we see tremendous opportunity to re-energise it, strengthen its connection with consumers and build it into an even bigger global business.
"We are proud to keep brewing BrewDog beer in Ellon, proud to honour its Scottish brewing heritage and fully committed to backing the people, beers, bars and brewing excellence that make BrewDog such a great beer brand.
"This campaign is a clear signal of our commitment to the brand, and it is one of many investments we intend to make as we drive BrewDog's next chapter of growth."
Let’s cut through the noise. The short-sighted bears on Reddit and Wall Street love to put a negative spin on Tilray because they are heavily shorting the stock. They are treating TLRY like it’s still just a struggling Canadian cannabis company. They are completely blind to what is actually happening here.
Ever since the 2021 merger under Aphria management, leadership has been quietly executing one of the greatest corporate transformations in market history. Tilray has transformed from a cannabis company pulling in roughly $50M annually in cannabis revenue into a diversified global Consumer Packaged Goods (CPG), Alcohol, and Pharma empire pacing towards a Billion+ in revenue by 2027.
The best part? They are doing this with Zero Net Debt and Hundreds of millions in cash working capital. They have the bulletproof balance sheet to outlast every single competitor.
Here is the ultimate masterlist of how Tilray is dominating globally while the shorts are trapped looking backward:
The "32M Shares Added" Myth Dismantled 🩳🤡
The bears are crying because Tilray added roughly 32 million shares over the last 6 months. They want you to think the sky is falling. Here is what they are intentionally hiding from you:
You don't build a multi-billion dollar global distribution footprint for free. Aphria management is trading paper shares for permanent, cash-flowing physical infrastructure.
I know we’ve all been frustrated with the price action lately, but I wanted to point out something from the recent updates that should actually give us confidence in the future.
For FY2026, Irwin Simon received ZERO annual performance bonus.
While some trolls will try to spin this as bad news, this is exactly what retail investors have been demanding for years. Here is why this is a massive positive for us:
Backward-looking critics (and conservative accountants) only look at past net losses. They completely miss the inflection point we are at. The expensive infrastructure buildout is already finished. Now, when the massive catalysts hit, that new revenue drops straight to the bottom line with high margins.
Here is exactly how we easily surpass those conservative 2027 cash flow goals:
1. The Veterans Affairs (VA) Imports Moat
Tilray is the only major player with a proven history of DEA-approved U.S. imports and federal-grade EU-GMP facilities. Once the DEA signs off on specific VA requests, Tilray completely bypasses Multi-State Operators (MSOs). MSOs are stuck operating on state-licensed levels—they cannot legally cross state lines or deal federally. Do any MSOs even have a federal cGMP operation? I'm certain they do not. That is the exact reason the DEA & FDA demand IMPORT. This gives TLRY an unassailable first-mover advantage with the US Federal Government.
2. France's Permanent Medical Market (Targeting Oct 1, 2026)
Tilray has been an official partner in France's strict medical trial since 2021. When the French Parliament reconvenes around October 1, 2026, the permanent medical reimbursement decree is expected to drop. This transitions France from a tiny trial cap of just 3,000 patients into a fully regulated, reimbursed market projected to scale to over 100,000+ patients by 2027—an explosive multiplier for our European distribution segment (CC Pharma).
3. Schedule III & The Cash Flow Math
Critics forget that Tilray already generated $18.2 million in positive operating cash flow (excluding working capital changes) for fiscal 2026—a massive 157% improvement from the year prior. Moving to Schedule III completely shifts the internal economics for the entire sector. Combine that with the new revenue from our debt-free BrewDog acquisition and the upcoming Carlsberg partnership starting January 1, 2027, and Tilray has a highly diversified, completely fresh set of revenue streams to smash expectations.
The infrastructure is paid for. The foundation is set. Major contract announcements are going to wake up the naysayers very soon.
Enjoy the coffee this morning. Our time will come. 💎🙌
ThePeanutsman @DerErdnussmann·6m> 🚨 Posted on X
$TLRY
Tilray CEO Irwin Simon gets ZERO annual performance bonus for FY2026.
Tilray missed key internal performance targets, including revenue and Adjusted EBITDA.
Simon’s target bonus: $4.1M
Actual bonus: $0
Performance matters. 🌿📊 #TLRY https://tilray.gcs-web.com/node/16476/html
manitoba harvest
The hardest part of back-to-school isn't the homework ✏️ it's getting everyone out the door fueled and ready. Stock up on protein powders that'll get the whole crew through early mornings and long days.